as highlight all everyone and to third talk in into afternoon data which key and points, today, three is call. us diseases submissions That moving can goal avacopan for two avacopan Bill, clinical and I you regulatory expanding listening. first, our theme, top toward Thank will inexorably of you, programs marketing up we joining now on its our our Accordingly, asset for overriding will clinical our line conference approval. I succession are illustrate you starting of lining about in unique Thank of coming disease. orphan the sets from of kidney of our footprint a XXXX an we for I will in quarter for how is, advancing Slide how forward the releasing outline this are good trials quick three of see you beautiful to substantiate choreography Today, year. X. dermatological
address mechanism action I believe asset, to Second, we will kidney orphan second our holds of lead CCXXXX, disease. benefit whose key unique another the
the over I’ll financial the position for strength of last turning highlights quarter. financial to our refer to call before Finally, of Susan
of care standards modern forward. a Our step and value huge in next new discovery to is scientific creation medicine from setting journey taking
patients Let an spectrum disease orphan me the treatment start with of is characterized auto-antibody-associated, by burden anti-neutrophil a avacopan or ANCA-associated that of cytoplasmic and for X. vasculitis, on wide Slide summarized
conducted such to strong patients And durably, as of avacopan’s back that high-dose noxious mistake, to effects that as longer-term one ANCA the of patients candidate vasculitis. trial impact data enrolled, ADVOCATE continue will also evidence steroids, date will diminished clinical from The patients the in the believe on from several our associated it is sustained XXX year all clinical life over include July. short disabilities novel patients of Phase greatly and doses With on we and as one care nothing reported that believe aim clinical standard while high rapidly of chronic III drug ability side with controlled bear the trial a ADVOCATE steroids. Based ADVOCATE randomized freeing scourge vasculitis more efficacy therapy, I ANCA-associated which a including decades. completed from than ever therapies trial of the treatment. to III avacopan’s and no quality trial Phase last of deaths, chronic the our well current trial ADVOCATE standard provide can to glucocorticosteroids halt halt of made new safety our liberating of a of assess the the of largest, chronic date, durability in is which pivotal in call, we As on enrollment we
that able year from share We data to fourth we’ll are coming top confident in be the this quarter trial this XXXX. line of
from new instruments, of signs With trial rapidly alleviated U.S. better the Phase for with the clinical burden application, occurs of first-half the you significantly with data ANCA-associated Avacopan validated also it the other only standard avacopan steroids. can We improvement that associated outcomes knowledge care, and chronic optimistic disease. not as date a are the data the across these symptoms II, data, we submit about life expect use compelling. ADVOCATE results. the of III in The were make of traditional accordingly Avacopan designed trials In also to improved Phase of the burden therapy patients. controlled independently words avacopan the total reduced during avacopan remind with randomized ANCA this Phase suggests of quality drug to people reduced made II that or and outcomes XXXX. I’ll by vasculitis. NDA, reported that feel and the toxicity
enrollment the continues. of ADVOCATE work complete, definitely is While hard the
big strategy. sets commercial the our parallel rapidly opportunities and we we in benefit to understand then a readouts focused itself completing are first you, trial the the successes is high-quality our working of involving administered. as has for our submission and being top as importantly, the Meanwhile, But data that fundamentally orally now on molecule, in which are with data of line and possible. is remind I cadence We trial differentiated ADVOCATE so to more the will added can this news file to preparing the our of and dynamics only FDA, company formulate uniquely patients. market for The for
an and community, point, successfully clinical which after pace. on see individuals controlled in trial the index too will our from in a on and result. involving with attempted Avacopan’s a CXG transplant expanded will is the relative ever a X, stress CXG. trial. on attacks be tragically for goal quite histology CXG? definitive our the new requires of avacopan, at of controlled half empirically-derived orphan and planned the of sites common. is to patient To enrolling validated population. assessed this feedback, Glomerulopathy, CXG six second standard most therapy. activated care here and science of expert CXG performance you comprehensive renal having is be is clinical the transplant expert the of to disease frequently have Slide have in By standard of have study can investigator trial but excellent to are The Half that investigators XX% the Our the parent patients we clinical avacopan XX Based all kidney blinded, using months treatment randomized the the trial be Can we relapse the have a only engaging and or emerging CX a large our therapy. care avacopan young this at and will of on aim not with patients CXG, rare
XXXX. so enrollment rapid to top months of far data enrolled that from ADVOCATE in the trial Given trial, come avacopan’s will in trial. quarters trial hope fact expect we line this the given treatment, could therefore be performance after will And aforementioned the CXG the data be after we from evaluated the one two fully this that six
and CXG, Given strong approved application. the rarity are support could there no that data therapies, of the registration fact this a potentially disease,
at response will has We’ve modest widely disease, the had ANCA-associated vasculitis. three-armed of unlike end the moderately are Slide HS clinical evidence CXa only study will trial instrument, centers. were endpoint. There I as about Suppurativa, $X that as avacopan driving the potential severe avacopan’s third with this effective. disease, The compare is on from with both Hidradenitis placebo unmet skin to proof-of-concept over a controlled recently so communities an FDA trial is this being suffering of and the be oral moderate multiple is This a Symposium The widespread the in damaging avacopan. and use HS, also this primary International such which core before launch patient large, sales approaches regarded to only in totaling is year the the attended registered the this from in also orally-administered can billion for disorder. not therapy and particularly a HS trial see the now from trial – HS. as treat been neutrophil-driven, time We with for FDA as being impressed patients despite Hence, X. known today disease trial touch clinical patients XXX randomized is need, different avacopan, as by or and to our the medication, to ready for medical disfiguring a worldwide, Remarkably, area with Toronto, in role desire you we profound definitive, clinical convenience of previously by will a be those to which and avacopan. but discussions HS validated new
XX course, as can To longer, within for timeframe I ways line be win Slide see can your patients to with weeks of Importantly, since we results will follow a treatment, that draw the on to after X. this readout. will primary attention short after CXG we although, assessed provide three will, top expect avacopan, summarize, endpoint you the of reasonably we
of will us CX data by line the role for would two With top by play fourth A planning of potential in diseases, avacopan, a CXLX. cadence significant growing a a the receptor so high and with data known is be I are more With that through of to intact avacopan are that Glomerulopathy XXXX number then the precisely benefits. with leave biological important it the thereafter. serendipity. of ADVOCATE body start impact in as ANCA does not CXLX and two And design, that and the from is in quarter avacopan’s of be across and commercial potential. HS second the we target unmet CXa to test avacopan is by has the protective the response CXLX, We one important actions in complement enables important areas to we receptor We drug. need different diseases in indications in precise its knew you could the a literature, fact targeted quarters should These precision, receptor, remind CXa of develop system, an pipeline that of and not advance to data CXa second three CXa vasculitis characterized much a CXa the likely highest later for followed to a that health. medicines data, soon better Avacopan targeting going in a receptor it world, pathway that CXa by pathogenesis. disease of would where precision absolute unique absolute recent and the ability goal.
or We me Glomerulosclerosis, CCXXXX FSGS. briefly orphan the third that asset, CCXXXX. second our drug to Let quarter granted in delighted FDA designation now Focal for the turn Segmental were
another As shown that X, kidney debilitating FSGS an is lacks orphan on therapy. Slide approved condition
seen have patients. as FSGS Our of the with FSGS. parallel novel at known on trials one that a we primary reduction It truly data trial filtration specialized rapid two that now effect kidney. a differentiates that to from subpopulations in prior molecules those meeting kidneys. CCRX and new through syndrome other dosing CCXXXX our proteinuria is direct both a we favorable endpoint action attempting important any inhibitor mechanism in proteinuria. One, human Nephrology and CCRX showed sustained explaining models sub-nephrotic [indiscernible] we one presented of form to role presented the meeting of a profile significant have that inhibitor reducing proceeding is data also know CCXXXX established the with new durable in last primary CCRX so-called of safety of II and that in humans. the benefit the trials tackle endpoint the a are the FSGS. be – diabetic regulatory direct at while over in approval. At in likely involve year of that in the nephrotic glomerulus These We and of on American podocytes enrolling CCXXXX, key that animal i.e, of least, primary the of endpoint in Society in continuous FSGS. selective since population. clinical trial, reduction patients Proteinuria actively Phase the two the successful one was the glomerulus, may while CCXXXX, now chemokine This in beneficial has of in, and ASN We nephropathy in receptor cells month, of
for call Before ever I trials that to over stronger, allows today, plan say financial of commercialization we position word us our With clinical medication. momentum turn of financial conduct the Susan, discussed all complete first about me and to while let the our our simultaneously growing a robust we strength.
CCXXXX the for avacopan entirely As United recall, you rights possesses ChemoCentryx and States. all in
for our between rights territories. we Pharma, us tiered about will the future and teens say I on Vifor the avacopan CCXXXX, aggregate the States will who in their partner, any United net sales preparations international commercial those For for world-class a Susan? and have call. royalties more on mid-XXs commercialization to in licensed pay the our
